** Shares of Divi's Laboratories DIVI.NS rise as much as
3.2% to 3,198 rupees, biggest pct gain since May 9
** Brokerage firm Jefferies upgrades DIVI to "buy" from
"underperform;" PT raised to 3,610 rupees from 2,550 rupees
** Q4 Revenue/EBITDA declined 23%/56% YoY but was ahead of
estimates - Jefferies
** Adds, co should be back to achieving mid/high teens
revenue growth from Q2FY24 with EBITDA growing at a faster pace
due to leverage benefits and softening input costs
** Besides, brokerage raises FY24/25 EPS estimates by 4-13%
** Analysts at Motilal Oswal, too, raise DIVI's earnings
estimates for FY24/FY25 by 7%/6%
** More than 764,000 shares change hands by 11:20 a.m. IST,
1.2x 30-day avg of 614,371 shares
** Four of the 22 analysts covering the stock have a "buy"
or "strong buy" rating, 10 "hold," while 8 rate it "sell" or
"strong sell;" median PT is 2,865 rupees - Refinitiv IBES data
(Reporting by Ashna Teresa Britto in Bengaluru)
((AshnaTeresa.Britto@thomsonreuters.com ; ( +91 8078332441))